Form 4 for URGN UroGen Pharma Ltd.
Accepted 2025-07-30 00:00:00 ET · period of report 2025-07-28 · accession 0001437749-25-023961 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-30 | 2025-07-28 | URGN | Schoenberg Mark | Chief Medical Off | S - Sale+OE | $19.14 | -5,149 | 158.2K | -3% | -$98.6K | |
| 2025-07-30 | 2025-07-28 | URGN | Schoenberg Mark | Chief Medical Off | M - OptEx | — | +10.0K | 163.4K | +7% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-07-28 | S | D | 5,149 | $19.14 | 158,229 | D | — | — | (F3) Represents shares sold to satisfy withholding tax obligations upon the settlement of performance stock units. |
| 2 | Common | Ordinary Shares | 2025-07-28 | M | A | 10,000 | — | 163,378 | D | — | — | (F1) Represents the settlement of performance stock units granted on January 31, 2024 that vested upon the achievement of a corporate milestone event. (F2) Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer. |